Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/12/06 00:22:20」(JST)

wiki en

Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers.^[1] A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".^[2]

Uses

It is used in the treatment of high blood pressure.^[3]

It has been proposed for use in treatment of essential tremor.^[4]

Recommended dosage 10 - 30 mg

References

^ Zhao, Jin; Golozoubova, Valeria; Cannon, Barbara; Nedergaard, Jan (July 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Can J Physiol Pharmacol 79 (7): 585–593. doi:10.1139/cjpp-79-7-585. PMID 11478592.
^ Hara, Youichi; Sato, Etsuro; Miyagishi, Akira; Aono, Shunzi; Nakatani, Hiroshi (1979). "新しいβ-受容体遮断薬，dl-2-(3'-t-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)-thiazole hydrochloride (S-596) の薬理作用" [Pharmacological properties of dl-2-(3'-t-butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochloride (S-596), a new β-adrenergic blocking agent]. Folia Pharmacologica Japonica (in Japanese (English abstract)): 707–720. doi:10.1254/fpj.75.707. ISSN 1347-8397.
^ Wu, Haiying; Zhang, Yuqing; Huang, Jianfeng; Zhang, Yuhui; Liu, Guozhang; Sun, Ningling; Yu, Zhenqui; Zhou, Yanrong (September 2001). "Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers" (PDF). Hypertension Research 24 (5): 605–10. doi:10.1291/hypres.24.605. ISSN 1348-4214. PMID 11675958.
^ Lee, Kwang-Soo; Kim, Joong-Seok; Kim, Jae-Woo; Lee, Won-Yong; Jeon, Beum-Seok; Kim, Dongjae (August 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor". Parkinsonism & Related Disorders 9 (6): 341–347. doi:10.1016/S1353-8020(03)00029-4. PMID 12853233.

External links

(Japanese) Almarl アルマール (PDF) Dainippon Sumitomo Pharma. April 2002.
(Japanese) Official Dainippon Sumitomo Pharma Website

http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=92

This article about an amine is a stub. You can help Wikipedia by expanding it.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 安定狭心症の管理における硝酸塩 nitrates in the management of stable angina pectoris

English Journal

Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension?

Nakamura K, Fujio H.
Circulation journal : official journal of the Japanese Circulation Society.Circ J.2009 Dec;73(12):2212-3.
PMID 19940372

Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats.

Ishikawa M, Sato N, Asai K, Takano T, Mizuno K.SourceDepartment of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Circulation journal : official journal of the Japanese Circulation Society.Circ J.2009 Dec;73(12):2337-41. Epub 2009 Oct 13.
BACKGROUND: It is unclear how much the sympathetic nervous system is involved in the development of pulmonary arterial hypertension (PAH). The present study examined whether or not a pure alpha/beta-adrenergic receptor blocker (arotinolol) could prevent the development of PAH and right ventricular h
PMID 19822980

Japanese Journal

Effects of a Pure α/β-Adrenergic Receptor Blocker on Monocrotaline-Induced Pulmonary Arterial Hypertension With Right Ventricular Hypertrophy in Rats

ISHIKAWA Masaya,SATO Naoki,ASAI Kuniya,TAKANO Teruo,MIZUNO Kyoichi
Circulation journal : official journal of the Japanese Circulation Society 73(12), 2337-2341, 2009-11-20
… The present study examined whether or not a pure α/β-adrenergic receptor blocker (arotinolol) could prevent the development of PAH and right ventricular hypertrophy (RVH) in a rat model of monocrotaline (MCT)-induced PAH. … Methods and Results: The heart rate, arterial blood pressure (BP), left ventricular pressure, pulmonary artery pressure (PAP), and right ventricular pressure (RVP) were measured after administration of arotinolol or saline for 2 weeks. …
NAID 10025938662

塩酸アロチノロール製剤の品質評価 : 先発医薬品と後発医薬品の比較

山崎啓之,古屋弓子,竹元瑞絵,瀬戸口奈央,日高宗明,岩切智美,奥村学,児玉裕文,有森和彦
医療薬学 32(9), 898-905, 2006-09-10
We evaluated the quality of the branded product (two presentations: 5 and 10mg) and generic versions (nine products: one of them 5mg and the other eight 10mg) of arotinoiol hydrochloride through disso …
NAID 110004809863

29) arotinolol投与によりたこつぼ型心筋症を来した褐色細胞腫の一例

久原康史,高島浩明,桜井春彦,服部和樹,塚本英人
Circulation journal : official journal of the Japanese Circulation Society 66(supplement III), 1062, 2002-10-20
NAID 110002688151

Related Pictures

★リンクテーブル★

リンク元	「アロチノロール」
拡張検索	「arotinolol hydrochloride」

「アロチノロール」

Arotinolol
Systematic (IUPAC) name
	(RS)-5-(2-{[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl}- 1,3-thiazol-4-yl)thiophene-2-carboxamide
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ Prescription only;
Routes	Oral
Pharmacokinetic data
Bioavailability	2h
Half-life	10h
Identifiers
CAS number	41287-43-8
ATC code	None
PubChem	CID 2239
ChemSpider	2152
UNII	394E3P3B99
KEGG	D07465
ChEMBL	CHEMBL93298
Chemical data
Formula	C15H21N3O2S3
Mol. mass	371.54 g/mol
	SMILES CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O;
	InChI InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20) ; Key:BHIAIPWSVYSKJS-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: arotinolol
化: 塩酸アロチノロール arotinolol hydrochloride
商: アルマール、アストニール、アセメール、アナシロール、アロチノイル、アロチノロール塩酸塩、アロチノン、セオノマール
関: 不整脈用剤

降圧薬;α1+β遮断薬

「arotinolol hydrochloride」

　　[★] アロチノロール。塩酸アロチノロール

[pmid11478592-1] Zhao, Jin; Golozoubova, Valeria; Cannon, Barbara; Nedergaard, Jan (July 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Can J Physiol Pharmacol 79 (7): 585–593. doi:10.1139/cjpp-79-7-585. PMID 11478592.

[2] Hara, Youichi; Sato, Etsuro; Miyagishi, Akira; Aono, Shunzi; Nakatani, Hiroshi (1979). "新しいβ-受容体遮断薬，dl-2-(3'-t-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)-thiazole hydrochloride (S-596) の薬理作用" [Pharmacological properties of dl-2-(3'-t-butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochloride (S-596), a new β-adrenergic blocking agent]. Folia Pharmacologica Japonica (in Japanese (English abstract)): 707–720. doi:10.1254/fpj.75.707. ISSN 1347-8397.

[pmid11675958-3] Wu, Haiying; Zhang, Yuqing; Huang, Jianfeng; Zhang, Yuhui; Liu, Guozhang; Sun, Ningling; Yu, Zhenqui; Zhou, Yanrong (September 2001). "Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers" (PDF). Hypertension Research 24 (5): 605–10. doi:10.1291/hypres.24.605. ISSN 1348-4214. PMID 11675958.

[pmid12853233-4] Lee, Kwang-Soo; Kim, Joong-Seok; Kim, Jae-Woo; Lee, Won-Yong; Jeon, Beum-Seok; Kim, Dongjae (August 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor". Parkinsonism & Related Disorders 9 (6): 341–347. doi:10.1016/S1353-8020(03)00029-4. PMID 12853233.

匿名

検索

案内

案内

arotinolol